- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Public drug program spending share for generics in Canada by province 2017
Public drug program spending share for generics in Canada by province 2017
Generic drugs share of total public drug program spending in Canada by province in 2017*
by Matej Mikulic,
last edited
Nov 26, 2018
This statistic shows the percentage of the total public drug program expenditures for generic drugs in Canada by province in 2017. In that year, 36.8 percent of total drug program spending in New Brunswick was for generic drugs.
Generic drugs share of total public drug program spending in Canada by province in 2017*
Loading statistic...
Expand statistic
| Share of total public drug program spending | |
|---|---|
| Alberta | 30% |
| British Columbia | 31.6% |
| Manitoba | 30.1% |
| New Brunswick | 36.8% |
| Newfoundland & Labrador | 47.1% |
| Nova Scotia | 38.5% |
| Ontario | 27.7% |
| Prince Edward Island | 42.6% |
| Quebec | 34.9% |
| Saskatchewan | 25.9% |
| Yukon | 31.6% |
| First Nations and Inuit Health Branch | 40.6% |
| Share of total public drug program spending | |
|---|---|
| Alberta | 30% |
| British Columbia | 31.6% |
| Manitoba | 30.1% |
| New Brunswick | 36.8% |
| Newfoundland & Labrador | 47.1% |
| Nova Scotia | 38.5% |
| Ontario | 27.7% |
| Prince Edward Island | 42.6% |
| Quebec | 34.9% |
| Saskatchewan | 25.9% |
| Yukon | 31.6% |
| First Nations and Inuit Health Branch | 40.6% |
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Nov 26, 2018
This statistic shows the percentage of the total public drug program expenditures for generic drugs in Canada by province in 2017. In that year, 36.8 percent of total drug program spending in New Brunswick was for generic drugs.
- Show sources information
- Show publisher information
- Release date
- November 2018
- Region
- Canada
- Survey time period
- 2017
- Supplementary notes
- * Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
Free access to basic statistics
Source
- Show sources information
- Show publisher information
- Release date
- November 2018
More information
- Region
- Canada
- Survey time period
- 2017
- Supplementary notes
- * Currently, the Northwest Territories and Nunavut do not submit data to NPDUIS.
Other statistics on the topic
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
U.S. brand and generic prescription drug revenue 2005-2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2017
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2017
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2017
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by payerPercentage savings through generic drug usage in the U.S. by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by age groupSavings through generic drug usage in the U.S., by age group share 2017
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Public drug program spending share for seniors in Canada by top drug classes 2017
- Public drug program spending for seniors in Canada by top drug classes 2017
- Public drug program spending for non-seniors in Canada by top drug classes 2017
- Public drug program spending share for non-seniors in Canada by province 2017
- Public drug program spending share for seniors in Canada by province 2017
- Share of paid beneficiaries of public drug program spending in Canada 2017
- Private sector funded total drug spending in Canada by top drug classes 2013
- Public drug program spending share for non-seniors in Canada by top drug classes 2017
- Public drug program spending in Canada by top 10 drug classes 2017
- Private sector funded drug spending Canada by top drug classes share 2013
- Public drug program spending in Canada by top drug classes 2017
- Public drug program spending in Canada by therapy share 2017
- Drug spending by Rx and non-Rx in Canada by type 1975-2018
- Share of drug spending in Canada by type and finance source 2018
- Expenditures dedicated to drugs as share of total health spending in Canada 2005-2018
- Distribution of public health spending in Canada by source of finance 1975-2018
- Public health spending per capita in Canada by source of finance 1975-2018
- Per capita public and private health spending in Canada 1975-2018
- Health spending in Canada by sector 1975-2018
- Drug spending as percent of total health in Canada by province 2018
Studies
- Prescribed Drug Spending in Canada, 2018
- Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans: 2...
- Patented Medicine Prices Review Board - Annual Report 2017
- Drug Use Among Seniors in Canada, 2016
- Recent Trends in Hospital Drug Spending and Manufacturer Shortages (2019)
- Meds Entry Watch 2017
- Prescribed Drug Spending in Canada, 2017
- Patented Medicine Prices Review Board - Annual Report 2016
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2006 to 2015
- Meds Entry Watch 2016
- Prescribed Drug Spending in Canada, 2013
- Prescribed Drug Spending in Canada, 2016
- Compass Rx - Annual Public Drug Plan Expenditure Report 2012/13
- Patented Medicine Prices Review Board - Annual Report 2013
- Patented Medicine Prices Review Board - Annual Report 2014
Statistics on "Generics and biosimilars"
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
- Top companies based on unbranded generics U.S. market share during 2016-2017*
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)
- Percentage of savings through generic drug usage in the United States in 2017, by payer
- Percentage of savings through generic drug usage in the United States in 2017, by age group
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)
- Number of biosimilars in development worldwide as of October 2017, by country
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*
- Distribution of top 10 drug classes in Canada by public drug program spending on seniors in 2017*
- Top 10 drug classes in Canada by total public drug program spending on seniors in 2017 (in million Canadian dollars)*
- Top 10 drug classes in Canada by total public drug program spending on non-seniors in 2017 (in million Canadian dollars)
- Distribution of total public drug program spending on non-seniors in Canada by province in 2017*
- Distribution of total public drug program spending on seniors in Canada by province in 2017*
- Distribution of paid beneficiaries from total public drug program spending in Canada in 2017*
- Top 10 drug classes by total drug spending funded by private sector in Canada in 2013 (in million Canadian dollars)
- Distribution of top 10 drug classes in Canada by total public drug program spending on non-seniors in 2017*
- Top 10 drug classes by total public drug program spending in Canada in 2017 (in million Canadian dollars)*
- Top 10 drug classes by share of total drug spending funded by private sector in Canada in 2013*
- Top 10 drug classes by share of total public drug program spending in Canada in 2017*
- Distribution of total public drug program spending in Canada by therapy in 2017*
- Expenditure on prescribed and non-prescribed drugs in Canada from 1975 to 2018 (in million Canadian dollars)
- Distribution of total drug expenditures in Canada by type and source of finance in 2012 and 2018
- Expenditure on drugs as percent of total health spending in Canada from 2005 to 2018
- Distribution of total public health expenditure in Canada by source of finance from 1975 to 2018
- Per capita public health expenditure in Canada by source of finance from 1975 to 2018 (in Canadian dollars)
- Public and private health expenditure per capita in Canada from 1975 to 2018 (in Canadian dollars)
- Total health expenditure in Canada by sector from 1975 to 2018 (in million Canadian dollars)
- Drug expenditure as percentage of total health spending in Canada by province in 2018*
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Please log in to access our additional functions
Register in seconds and access exclusive features.
Basic Account
|
Instant Access
Premium Account
| ||
|---|---|---|---|
Our services
Click the question mark for further information | Free |
$49 per month*
| |
| Basic statistics | |||
| Premium statistics | |||
|
Graph download
| |||
| Download PDF | |||
|
Excel download
| |||
| Register | Purchase now | ||
*Duration: 12 months, billed annually, single license
Yes, let me download!
...and make my research life easier.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.